Paul Thurk was a Managing Director with ARCH Venture Partners. (1970-2021)

Mr. Thurk joined ARCH in 2000 as a Kauffman Fellow. In 2011, he established ARCH’s European office in Dublin, Ireland to focus on European-sourced technology and investment opportunities.  Mr. Thurk was co-founder and initial CEO of Innovalight (acquired by DuPont) and also CoolEdge Lighting. He co-founded Carrick Therapeutics and Genomics Medicine Ireland (acquired by WuXi NextCODE). He has participated in the development of Kotura (acquired by Mellanox), Nitronex (acquired by MACOM), Cambrios, Semprius, Movidius (acquired by Intel), Sana Biotechnology, Luna DNA, BioPalette Japan, and others.  He is co-founder and current CEO of Pretzel Therapeutics.

Mr. Thurk originally began ARCH focusing on semiconductors, advanced materials, electronics and optoelectronics and played a key role in ARCH’s partnership with Los Alamos and Sandia National Laboratories in cooperation with the U.S. Department of Energy. More recently, he has been focused on genomics, cell and gene therapies, and other novel therapeutics.

Prior to ARCH, Mr. Thurk was a Director of Operations for NABS, a New York City based supplier of electronics components, where he specialized in supply chain management programs and established operations in several countries, ending in Taipei as the head of Asia Pacific.

Mr. Thurk holds a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from the University of Texas at Austin.

ALL Managing Directors